13140-47-1

Usage

Uses

Used in Pharmaceutical Research and Development:
1-Phenyl-3-propyl-2-thiourea is used as a competitive inhibitor of thyroid peroxidase for the study of thyroid hormone synthesis. This application is crucial in understanding the role of thyroid hormones in various physiological processes and their dysregulation in conditions such as hyperthyroidism.
Used in Treatment of Hyperthyroidism:
1-Phenyl-3-propyl-2-thiourea is used as an antithyroid drug for the treatment of hyperthyroidism. It helps in managing the symptoms and reducing the overproduction of thyroid hormones, thereby normalizing thyroid function.
Used in Thyroid Cancer Research:
1-Phenyl-3-propyl-2-thiourea is used as a potential therapeutic agent in the study and treatment of thyroid cancer. Its ability to inhibit thyroid hormone synthesis makes it a candidate for exploring its effects on cancer cells that rely on these hormones for growth and proliferation.
Used in Animal Studies:
1-Phenyl-3-propyl-2-thiourea is used in animal models to investigate the impact of thyroid hormone levels on various physiological processes. This helps researchers understand the broader implications of thyroid hormone dysregulation and develop targeted therapies.
Used in Antioxidant and Cancer Prevention Research:
1-Phenyl-3-propyl-2-thiourea is used in research exploring its potential role in protecting against oxidative stress and preventing the development of certain types of cancer. Its antioxidant properties and effects on cellular processes are of interest in the context of cancer prevention and treatment strategies.

InChI:InChI=1/C10H14N2S/c1-2-8-11-10(13)12-9-6-4-3-5-7-9/h3-7H,2,8H2,1H3,(H2,11,12,13)

Upstream product

• 107-10-8 propylamine 
• 103-72-0 phenyl isothiocyanate 
• 628-30-8 n-Propyl isothiocyanate 
• 62-53-3 aniline 

Downstream Products

• 24622-33-1 N-propylbenzo[d]thiazol-2-amine 
• 63543-89-5 3-propyl-2-(phenylimino)-1,3-thiazolidin-4-one 
• 129226-13-7 4-Phenyl-5-[(E)-propylimino]-4,5-dihydro-[1,2,4]thiadiazol-3-ylamine 
• 85285-37-6 1-phenyl-5-(propyl amino)(1H)tetrazole 
• 6685-76-3 phenylguanidinium hydrogencarbonate 
• 155231-36-0 {RhCl(CO)2}2(SC(NHC₆H₅)(NHC₃H₇)) 
• 1445905-01-0 1-phenyl-3-propyl-2-thioxo-4,5-imidazolidinetrione 
• 92971-62-5 1-phenyl-3-propylcarbodiimide 
• 91467-19-5 1-phenyl-3-propyl-2,4,5-imidazolidinetrione 
• 143039-20-7 {(μ-H)Ru3{μ3-SC(NHPr)NPh}(CO)9} 

Relevant academic research and scientific papers

5-Arylidene-2-imino-4-thiazolidinones: Design and synthesis of novel anti-inflammatory agents

The synthesis and pharmacological activity of 5-arylidene-2-imino-4- thiazolidinones (3a-8a) are described. All derivatives exhibited significant activity levels in models of acute inflammation such as carrageenan-induced paw and pleurisy edema in rats. I

Preparation method of thiourea alkylation derivative

The invention discloses a preparation method of a thiourea alkylation derivative, which comprises the following steps: stirring an aldehyde, N-arylthiourea, trichlorosilane and Lewis base in an organic solvent at a range of -10 DEG C to room temperature for reaction, and carrying out after-treatment to obtain the thiourea alkylation derivative, wherein the molar ratio of the aldehyde to the N-arylthiourea is 1:2 to 2:1, the molar ratio of the aldehyde to the Lewis base is 1:(0.01-0.20), the molar ratio of the aldehyde to trichlorosilane is 1:(1-2), R1 is a C1-C5 saturated alkyl group, or an unsubstituted or substituted aromatic ring, and R2 is H, an electron withdrawing substituent or an electron donating substituent. According to the method, trichlorosilane is catalyzed by the micromolecular Lewis base, reductive alkylation of thiourea is realized, synthesis can be realized by a one-pot method, and the method is simple to operate, short in reaction time, low in substrate toxicity, lowin cost, easy to obtain, mild in reaction condition and high in safety.

Synthesis, crystal structure, anticancer and molecular docking studies of quinolinone-thiazolidinone hybrid molecules

A new series of quinolone-thiazolidinone hybrid molecules 8a-o were prepared. Quinoline compounds were synthesized by Meth-Cohn synthesis and were condensed with 2,3-disubstituted thiazolidinone. These molecules were screened for their anticancer activities against MDA-MB-231 and MCF-7 cell line using MTT assay. Potent compounds were tested for their cytotoxicity on normal HEK 293 cell lines and most potent compound was tested for its cell cycle analysis. Molecular docking and molecular dynamic studies were performed on human N-acetyl transferase (hNAT-1) protein using Schrodinger molecular docking toolkit. Compound 8n emerged as potent with IC50 8.16?μM against MDA-MB-231 cell line followed by 8e with IC50 17.68?μM. Compound 8n arrested cell cycle at G2/M phase and was non-toxic to human normal kidney cell line. The potent compound 8n binds well with human NAT-1 protein with remarkable hydrogen bonding and π–π interactions. Molecular dynamic studies of 8n further confirm the target for these molecules. Target quinolinone-thiazolidinones were found to be new class of compounds targeting hNAT-1 and can serve as new lead compounds in drug discovery.

Facile synthesis of phthalidyl fused spiro thiohydantoins through silica sulfuric acid induced oxidative rearrangement of ninhydrin adducts of thioureas

A one-pot three-component sequential synthetic protocol produces structurally and biologically important phthalidyl fused spiro N,N′-disubstituted thiohydantoins from readily available aromatic isothiocyanates, primary amines and ninhydrin. In this three-step synthesis while the initial two steps are catalyst-free, in the final step silica sulfuric acid (SSA) induces an oxidative rearrangement in [3.3.0]-bicyclic 1,2-diol adducts of ninhydrin and thioureas under solvent-free condition to generate the final products spiro-fused thiohydantoins. The adequate acidity of SSA in cooperation with moderate oxidizing property promotes a facile oxidative rearrangement in 1,2-diol intermediates to produce the spiro-fused thiohydantoins with diverse functionalities. Easy recyclability of SSA, good to excellent yield of the products, wider substrate scope, shorter reaction time, solvent-free two steps out of three and high atom economy make this method attractive and practicable.

Synthesis of metronidazole based thiazolidinone analogs as promising antiamoebic agents

Metronidazole and its derivatives are widely used for the treatment of amoebiasis. However, metronidazole is considered as the standard drug but it has many side effects. The present study describes the synthesis of a series of metronidazole based thiazolidinone analogs via Knoevenagel condensation of 4-[2-(2-methyl-5-nitro-1H-imidazole-1-yl)ethoxy]benzaldehyde 1 with various thiazolidinone derivatives 2–14 to get the new scaffold (15–27) having better activity and lesser toxicity. Six compounds have shown better efficacy and lesser cytotoxicity than the standard drug metronidazole towards HM1: IMSS strain of Entamoeba histolytica. These compounds may combat the problem of drug resistance and might be effective in identifying potential alternatives for future drug discovery against EhOASS.

Nickle Catalysis Enables Access to Thiazolidines from Thioureas via Oxidative Double Isocyanide Insertion Reactions

An efficient synthesis of thiazolidine-2,4,5-triimine derivatives was developed via Ni-catalyzed oxidative double isocyanide insertion to thioureas under air conditions, in which thioureas play three roles as a substrate, a ligand, and overcoming isocyanide polymerization. The reaction is featured by employing a low-cost and low loading Ni(acac)2 catalyst, without any additives, and high atom economy. This is the first example to directly apply a Ni(II) catalyst in oxidative double isocyanide insertion reactions.

A general synthetic method for the formation of substituted 5-aminotetrazoles from thioureas: a strategy for diversity amplification.

A general method for the synthesis of 5-aminotetrazoles is outlined using the mercury(II)-promoted attack of azide anion on a thiourea. The reaction proceeds through a guanyl azide intermediate, which undergoes electrocyclization to the tetrazole. The method is high yielding and provides access to mono-, di-, and trisubstituted 5-aminotetrazoles, targets of potential interest for combinatorial library development.